Cardiac event prevention medication does not work for 1 in 6 people

In clinical research studies, the effectiveness of cardiovascular medications used for preventing heart attacks, strokes and certain types of blood clots has been shown to be affected by DNA changes. In some cases, the risk of a second heart attack, stroke or death was up to 3x higher. Changes in one gene in particular, CYP2C19 was found to be important in understanding this increase in risk. DNA changes in CYP2C19 that reduce the metabolizing of cardiac prevention medications resulted in less or no protection for the patient.

How Kailos can help you

With the Kailos test, you will discover what DNA changes have been shown to be related to how medications are metabolized. If you are just beginning therapy, this information can be information that a treating physician incorporates into the selection process. These DNA changes could also provide physicians insights into reasons why treatments may not be working as effectively as expected or are producing more side effects than expected. At Kailos Genetics, we sequence DNA and compare it to research and clinical study data so a physician can make genetics a part of their decision making.

Cardiac Event Prevention, $99


A variety of scientific and clinical research groups around the world have studied the relationships between many genes and pain medications especially clopidogrel. From those studies, one gene has been identified for extensive studies: CYP2C19. In many of these studies, different forms of this gene was related, although not necessarily causative, of how effective clopidogrel performed. Guidelines issued by the Clinical Pharmacogenomics Implementation Consortium contain extensive information on the studies reviewed:

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CP2C19 Genotype and Clopidogrel Therapy: 2013 Update doi: 10.1038/clpt.2013.105

FDA Drug Safety Communication: FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. (Issued 8/03/2017)

Other cardiac management medications have studies that, while informative on metabolism rates, are not supported by FDA communications or CPIC guidelines at this time.